A clinical study of bevacizumab to analyze a correlation of efficacy and the VEGF-related gene cluster for Patients with Advanced Non- Squamous Non-Small Cell Lung Cancer -KTOSG1003- - KTOSG1003 study

Department of Respiratory Medicine, Kumamoto University Hospital0 个研究点目标入组 30 人开始时间: 2012年3月31日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1)CNS metastasis. (2)History of treatment for brain metastasis. (3)History of active double cancer. (4)History of hemoptysis or hemosputum. (5)Evidence of bleeding diathesis or coagulopathy. (6)With great vessel invasion or cavity in tumor. (7)Radiotherapy for thoracic lesions. (8)History of severe heart disease. (9)Superior vena cava syndrome. (10)Spinal cord compression (11)Current or previous history (within the last 1 year) of symptomatic cerebrovascular disease. (12)Non-healing bone fracture and wound. (13)Active infectious disease in need of intravenous administration of anti-bacterial, anti-fungal, or anti-viral drugs. (14)Plan of the operation. (15)Uncontrollable thrombosis. (16)Uncontrollable gastrointestinal ulceration. (17)Current or previous(within the last 1 year)history of GI perforation. (18)Uncontrollable systemic disease (hyper tension or diabetes mellitus). (19)Severe cardiac disease. (20)Interstitial pneumonia or pulmonary fibrosis detectable on X-ray. (21)Peripheral neuropathy > Grade2. (22)With a history of drug sensitivity. (23)History of bevacizumab treatment in the past. (24)History of pregnancy or lactation. (25)No intention to practice birth control. (26)Registration to other trial. (27)Patients whose participation in the trial is judged to be inappropriate by the attending doctor.

发起方

Department of Respiratory Medicine, Kumamoto University Hospital